{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024753", "CSN": null, "TRF": "ORD_1503257_01", "MRN": "35462818", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1226604", "clinicalId": "1227974", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1503257_01", "SampleName": "US1439901.01", "Version": "0", "Sample": {"FM_Id": "ORD_1503257_01", "SampleId": "US1439901.01", "BlockId": "S111-79465 (N22-18692 From Mackay Memorial Hospital)", "TRFNumber": "ORD_1503257_01", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2022_11_14", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}]}, "TumorPurity": "60", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10018", "MRN": "35462818", "FullName": "\u9673\u6f54\u654f", "FirstName": "Chieh Min", "LastName": "Chen", "SubmittedDiagnosis": "Leiomyosarcoma, metastatic", "Gender": "Female", "DOB": "1983_09_26", "OrderingMD": "\u59dc\u4e43\u6995", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2022_11_01", "ReceivedDate": "2022-12-01 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "24", "clinicalTrialCount": "1", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ASMTL", "isVUS": "true", "variantName": "T280I"}, {"geneName": "CIC", "isVUS": "true", "variantName": "S734L"}, {"geneName": "CREBBP", "isVUS": "true", "variantName": "Q278P"}, {"geneName": "EPHB1", "isVUS": "true", "variantName": "E605K"}, {"geneName": "ERG", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ETV5", "isVUS": "true", "variantName": "rearrangement,rearrangement,rearrangement"}, {"geneName": "GRIN2A", "isVUS": "true", "variantName": "I876T"}, {"geneName": "IL7R", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MYCN", "isVUS": "true", "variantName": "A184S"}, {"geneName": "NF1", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "T440M"}, {"geneName": "STAG2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TLL2", "isVUS": "true", "variantName": "R343G"}, {"geneName": "U2AF1", "isVUS": "true", "variantName": "amplification"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "RICTOR", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "RICTOR encodes an mTOR_binding protein that forms part of the rapamycin_insensitive mTORC2 complex, a regulator of cell metabolism and the cytoskeleton (Sarbassov et al., 2004; 15268862, Jacinto et al., 2004; 15467718, Pearce et al., 2007; 17461779). RICTOR amplification has been reported in cancer (Cheng et al., 2014; ASCO Abstract 8027, Ruder et al., 2015; AACR Abstract 3576, Dabir et al., 2015; ASCO Abstract 7576, Ross et al., 2014; 24978188) and has been associated with clinical response to mTORC1/2 inhibition (Cheng et al., 2014; ASCO Abstract 8027, Kristeleit et al., 2015; ASCO Abstract 2592). In the Sarcoma Genome Project dataset, putative high_level amplification of RICTOR has been reported in 7% (2/27) of leiomyosarcomas (cBio_Barretina et al., 2010; 20601955). RICTOR overexpression has been observed particularly in well_differentiated leiomyosarcoma (Gibault et al., 2012; 22080063). Published data investigating the prognostic implications of RICTOR amplification in leiomyosarcoma are limited (PubMed, Jan 2022). RICTOR amplification may indicate sensitivity to mTORC1/2 inhibitors (Cheng et al., 2015; 26370156) or dual PI3K/mTOR inhibitors (Wicki et al., 2018; 29660598). A patient with RICTOR_amplified lung adenocarcinoma experienced SD for >18 months upon treatment with the dual mTORC1/2 inhibitor CC_223 (Cheng et al., 2015; 26370156), and a patient with RICTOR_amplified metastatic thymic carcinoma achieved a PR upon treatment with a pan_PI3K/mTORC1/2 inhibitor PQR309 (Wicki et al., 2018; 29660598). In contrast, no clinical benefit was reported for 4 patients with RICTOR_amplified small cell lung cancer treated with the mTORC1/2 inhibitor vistusertib (Park et al., 2020; 32584426) and additional trials of this compound were terminated due to lack of efficacy (Lee et al., 2019; 31315834).", "Include": "true", "ClinicalTrialNote": "RICTOR amplification may predict sensitivity to dual mTORC1/mTORC2 inhibitors, as well as dual PI3K/mTOR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT04337463", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "CD36", "Include": "true", "Alterations": {"Alteration": {"Name": "T111fs*22", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "T111fs*22"}}, "Interpretation": "CD36 encodes the thrombospondin receptor which is involved in cell adhesion. Preclinical studies have shown that decrease in CD36 expression in breast cancer is modulated by estradiol (Uray et al., 2004; 15050739). Somatic mutations of CD36 are generally rare in cancer, reported in 0_2.5% of various tumor types (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of CD36 alterations in cancer are generally limited (PubMed, 2022). In acute myeloid leukemia, high CD36 gene expression has been associated with poor outcomes and observed in chemotherapy_resistant leukemic cells (Farge et al., 2017; 28416471). There are no therapies to target genomic alterations in CD36.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MSH3", "Include": "true", "Alterations": {"Alteration": {"Name": "S8fs*17", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S8fs*17"}}, "Interpretation": "MSH3 encodes a DNA mismatch repair protein. Two MutS homolog (MSH) complexes, MSH2_MSH6 (MutS_alpha) and MSH2_MSH3 (MutS_beta), are responsible for recognition of mismatched bases (van Oers et al., 2013; 24013230). MSH3 and MutS_beta has also been shown to participate in double_strand break repair by homologous recombination (van Oers et al., 2014; 24013230, Dietlein et al., 2014; 24556366). MSH3 loss of function has been linked to the production of tetranucleotide microsatellite frameshift mutations termed EMAST (elevated microsatellite alterations at selected tetranucleotide repeats) (Haugen et al., 2008; 18922920, Lee at al., 2010; 20708618). The presence of EMAST has been recognized as a biomarker in multiple solid cancers with microsatellite instability (MSI) (Watson et al., 2014; 24691426). Inactivating MSH3 mutations found in cancer tend to be frameshift, missense, or allelic loss (Kim et al., 2013; 24209623, Ohmiya et al., 2001; 11470537, Laghi et al., 2012; 22496206, Plaschke et al., 2004; 14871813). Certain germline polymorphisms in MSH3 have been reported to increase the risk of various cancers including colorectal (CRC) (Miao et al., 2015; 26617824, Morak et al., 2017; 28528517, Duraturo et al., 2011; 21128252, Reeves et al., 2012; 21974800, Berndt et al., 2007; 17205513), breast (Miao et al., 2015; 26617824, Yang et al., 2015; 25927356), esophageal (Vogelsang et al., 2012; 22623965), prostate (Jafary et al., 2012; 23464402, Hirata et al., 2008; 18355840, Miao et al., 2015; 26617824), gastric (Ohmiya et al., 2001; 11470537), and head and neck squamous cell carcinoma (HNSCC) (Nogueira et al., 2015; 25598504). Inactivating germline polymorphisms have been associated with hereditary colorectal adenomatous polyposis (Adam et al., 2016; 27476653). MSH3 mutations have been reported with the highest incidence in endometrial (9.0%), stomach (3.6%), skin (3.4%), and CRC (1.9%) (cBioPortal, 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). MSH3 loss has been reported with the highest incidence in ovarian serous cystadenocarcinoma (3.3%), prostate adenocarcinoma (2.6%), and esophageal adenocarcinoma (1.1%) (cBioPortal, 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). MSH3 loss has been correlated with the late development and progression of a variety of sporadic cancers including lung, ovarian, bladder, breast, and colorectal tumors (Edelmann et al., 2000; 10706084, Plaschke et al., 2012; 22249440, Benachenhou et al., 1998; 9650548, Kawakami et al., 2004; 15541380, Benachenhou et al., 1999; 10098729, Plaschke et al., 2004; 14871813). Consistent with this observation, studies have suggested that MSH3 loss increases chromosomal instability in p53_driven tumor models (van Oers et al., 2013; 24013230). Certain germline polymorphisms in MSH3 have been associated with poor prognosis in CRC (Plaschke et al., 2004; 14871813), HNSCC (Nogueira et al., 2015; 25598504), non_small cell lung cancer (NSCLC) (Xu et al., 2015; 25966119), and pancreatic cancer (Dong et al., 2011; 21212431). However, in one study of patients with MLH1_deficient CRC, MSH3 loss was associated with improved post_surgery outcome (Laghi et al., 2012; 22496206). There are no targeted approaches to address MSH3 mutation or loss. However, preclinical studies in the context of MSH3_deficient cancer cells have demonstrated antitumor efficacy of DNA_PKcs inhibitors (Dietlein et al., 2014; 24556366) and PARP inhibitors such as olaparib (Takahashi et al., 2011; 21285347) and have shown increased chemosensitivity to cisplatin, oxaliplatin, and SN_38 (Park et al., 2013; 23724141, Takahashi et al., 2011; 21285347). However, these remain to be tested clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, 40% of which were leiomyosarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). Smaller studies have reported MSI at any level in a subset of leiomyosarcoma patients (Suwa et al., 1999; 10370164, Verelst et al., 2004; 15668899, Urso et al., 2012; 22782591, Amant et al., 2001; 11437928, Quade et al., 1999; 10079273, Risinger et al., 1995; 7585651), including MSI_H in two of seven cases (Risinger et al., 1995; 7585651, Nilbert et al., 2009; 19130300). The prognostic significance of MSI in leiomyosarcoma is unknown (PubMed, Jan 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RB1", "Include": "true", "Alterations": {"Alteration": {"Name": "rearrangement intron 1", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "rearrangement intron 1"}}, "Interpretation": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). RB1 mutations have been reported in up to 53% of leiomyosarcomas (Elvin et al., 2017; 28283584, Williams et al., 2020; 33015533). RB1 loss appears to play a role in the development of leiomyosarcoma; one study reported alterations in the Rb_cyclin D pathway in 90% of 23 leiomyosarcoma cases examined (Dei et al., 1996; 8644845). RB1 gene loss has been reported in leiomyosarcoma of the urinary bladder and loss of the RB1 locus on chromosome 13q14 occurs frequently in leiomyosarcoma (Svajdler et al., 2012; 22716012, Derr\u00e9 et al., 2001; 11232643, Gibault et al., 2011; 21125665). Published data investigating the prognostic implications of RB1 mutations in leiomyosarcoma are limited (PubMed, Feb 2022). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2019; 30373917, Oser et al., 2019; 30373918, Yang et al., 2022; 34741392), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RUNX1", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "RUNX1 encodes a transcription factor that is involved in developmental gene expression programs and hematopoiesis. It is a frequent site of translocation and mutation in myeloid cancers, and it functions as a tumor suppressor in this context (Rio_Mach\u00edn et al., 2012; 22102704, Silva et al., 2003; 12555067). Reports of RUNX1 translocations and mutations in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are common. RUNX1 plays a context_dependent role in epithelial cells and has been implicated as both a tumor suppressor and oncogene in different types of solid tumors (Scheitz and Tumbar, 2013; 23150456). RUNX1 amplification has been reported in B_lymphoblastic leukemia (Harewood et al., 2003; 12646943, Soulier et al., 2003; 12886264, Reichard et al., 2011; 21822204, Boucher et al., 2016; 26907657, Braekeleer et al., 2010; 20001241). RUNX1 alterations were not found in any of the leiomyosarcoma samples analyzed in COSMIC nor 27 samples analyzed in the MSKCC Sarcoma dataset (COSMIC, cBioPortal, Aug 2021)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). The frequency of RUNX1 rearrangement in solid tumors has not been evaluated (cBioPortal, COSMIC, PubMed, Oct 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of RUNX1 alterations in solid tumors are generally limited (PubMed, Jun 2022). There are no therapies available to directly target inactivating alterations in RUNX1. Limited clinical (Kuendgen et al., 2013; ASH Abstract 2757)(Inoue et al., 2014; 24608072) and preclinical (Buchi et al., 2014; 24300456) data suggest that RUNX1 alterations, rearrangements in particular, may be associated with sensitivity to DNMT inhibitors, such as the approved agents azacitidine and decitabine, and the BCL_2 inhibitor, venetoclax, in AML (Wei et al., 2018; ASH Abstract 333). However, multiple clinical studies have reported that RUNX1 is not a significant biomarker for efficacy of these therapies (Kuendgen et al., 2013; ASH Abstract 2757, Guadagnuolo et al., 2014; ASH Abstract 1030)(Braun et al., 2011; 21828134, Tobiasson et al., 2016; 26959885). Similarly, based on limited clinical (Odenike et al., 2008; 18981008) and preclinical (Barbetti et al., 2008; 17891169, Hu et al., 2011; 21518930, Bots et al., 2014; 24415537) evidence, RUNX1 rearrangements may predict sensitivity to HDAC inhibitors. However, further studies are required to establish clinical significance. There are no approved therapies that directly target RUNX1 amplification (Harrison et al., 2015; 25608562).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R342P", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R342P"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 alterations have been reported in 59% of leiomyosarcoma cases (P\u00e9rot et al., 2010; 20884963). In the Sarcoma Genome Project dataset, putative homozygous deletion of TP53 has been found in 10.6% of cases, including 3.7% (1/27) of leiomyosarcoma cases (cBio_Barretina et al., 2010; 20601955). Mutations in TP53 are associated with poor prognosis for patients with leiomyosarcoma (Yang et al., 2015; 26692951). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "06", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "06"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Leiomyosarcoma harbors a median TMB of 2.5 mutations per megabase (muts/Mb), and <1% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Sarcomas in general also harbor a median TMB of 2.5 muts/Mb, with angiosarcoma (13.4%) and malignant peripheral nerve sheath tumor (MPNST) (8.2%) having the highest percentage of cases with high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2022). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": {"Gene": "RICTOR", "Alteration": "amplification", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "RICTOR amplification may predict sensitivity to dual mTORC1/mTORC2 inhibitors, as well as dual PI3K/mTOR inhibitors.", "Include": "true"}}, "References": {"Reference": [{"number": "0", "ReferenceId": "15268862", "FullCitation": "Sarbassov DD, et al. Curr. Biol. (2004) pmid: 15268862", "Include": "true"}, {"number": "1", "ReferenceId": "15467718", "FullCitation": "Jacinto E, et al. Nat. Cell Biol. (2004) pmid: 15467718", "Include": "true"}, {"number": "2", "ReferenceId": "17461779", "FullCitation": "Pearce LR, et al. Biochem. J. (2007) pmid: 17461779", "Include": "true"}, {"number": "3", "ReferenceId": "24978188", "FullCitation": "Ross JS, et al. J. Clin. Pathol. (2014) pmid: 24978188", "Include": "true"}, {"number": "4", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "5", "ReferenceId": "22080063", "FullCitation": "Gibault L, et al. Mod. Pathol. (2012) pmid: 22080063", "Include": "true"}, {"number": "6", "ReferenceId": "26370156", "FullCitation": "Cheng H, et al. Cancer Discov (2015) pmid: 26370156", "Include": "true"}, {"number": "7", "ReferenceId": "29660598", "FullCitation": "Wicki A, et al. Eur. J. Cancer (2018) pmid: 29660598", "Include": "true"}, {"number": "8", "ReferenceId": "32584426", "FullCitation": "Park S, et al. Cancer (2020) pmid: 32584426", "Include": "true"}, {"number": "9", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "10", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "11", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "12", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "13", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "14", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "15", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "16", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "17", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "18", "ReferenceId": "15668899", "FullCitation": "Verelst SJ, et al. Hum. Pathol. (2004) pmid: 15668899", "Include": "true"}, {"number": "19", "ReferenceId": "22782591", "FullCitation": "Urso E, et al. Mol. Biol. Rep. (2012) pmid: 22782591", "Include": "true"}, {"number": "20", "ReferenceId": "11437928", "FullCitation": "Amant F, et al. Int. J. Gynecol. Cancer () pmid: 11437928", "Include": "true"}, {"number": "21", "ReferenceId": "10079273", "FullCitation": "Quade BJ, et al. Am. J. Pathol. (1999) pmid: 10079273", "Include": "true"}, {"number": "22", "ReferenceId": "7585651", "FullCitation": "Risinger JI, et al. Cancer Res. (1995) pmid: 7585651", "Include": "true"}, {"number": "23", "ReferenceId": "19130300", "FullCitation": "Nilbert M, et al. Fam. Cancer (2009) pmid: 19130300", "Include": "true"}, {"number": "24", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "25", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "26", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "27", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "28", "ReferenceId": "22102704", "FullCitation": "Rio_Mach\u00edn A, et al. Haematologica (2012) pmid: 22102704", "Include": "true"}, {"number": "29", "ReferenceId": "12555067", "FullCitation": "Silva FP, et al. Oncogene (2003) pmid: 12555067", "Include": "true"}, {"number": "30", "ReferenceId": "23150456", "FullCitation": "Scheitz CJ, et al. J. Cell. Biochem. (2013) pmid: 23150456", "Include": "true"}, {"number": "31", "ReferenceId": "12646943", "FullCitation": "Harewood L, et al. Leukemia (2003) pmid: 12646943", "Include": "true"}, {"number": "32", "ReferenceId": "12886264", "FullCitation": "Soulier J, et al. Leukemia (2003) pmid: 12886264", "Include": "true"}, {"number": "33", "ReferenceId": "21822204", "FullCitation": "Reichard KK, et al. Mod Pathol (2011) pmid: 21822204", "Include": "true"}, {"number": "34", "ReferenceId": "26907657", "FullCitation": "Boucher MO, et al. J Pediatr Hematol Oncol (2016) pmid: 26907657", "Include": "true"}, {"number": "35", "ReferenceId": "20001241", "FullCitation": "De Braekeleer E, et al. Leuk Lymphoma (2010) pmid: 20001241", "Include": "true"}, {"number": "36", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "37", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "38", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "39", "ReferenceId": "24608072", "FullCitation": "Inoue A, et al. J. Pediatr. Hematol. Oncol. (2014) pmid: 24608072", "Include": "true"}, {"number": "40", "ReferenceId": "24300456", "FullCitation": "Buchi F, et al. Epigenetics (2014) pmid: 24300456", "Include": "true"}, {"number": "41", "ReferenceId": "21828134", "FullCitation": "Braun T, et al. Blood (2011) pmid: 21828134", "Include": "true"}, {"number": "42", "ReferenceId": "26959885", "FullCitation": "Tobiasson M, et al. Oncotarget (2016) pmid: 26959885", "Include": "true"}, {"number": "43", "ReferenceId": "18981008", "FullCitation": "Odenike OM, et al. Clin. Cancer Res. (2008) pmid: 18981008", "Include": "true"}, {"number": "44", "ReferenceId": "17891169", "FullCitation": "Barbetti V, et al. Oncogene (2008) pmid: 17891169", "Include": "true"}, {"number": "45", "ReferenceId": "21518930", "FullCitation": "Hu Z, et al. Blood (2011) pmid: 21518930", "Include": "true"}, {"number": "46", "ReferenceId": "24415537", "FullCitation": "Bots M, et al. Blood (2014) pmid: 24415537", "Include": "true"}, {"number": "47", "ReferenceId": "25608562", "FullCitation": "Blood (2015) pmid: 25608562", "Include": "true"}, {"number": "48", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "49", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "50", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "51", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "52", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "53", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "54", "ReferenceId": "20884963", "FullCitation": "P\u00e9rot G, et al. Am. J. Pathol. (2010) pmid: 20884963", "Include": "true"}, {"number": "55", "ReferenceId": "26692951", "FullCitation": "Yang CY, et al. Am J Transl Res (2015) pmid: 26692951", "Include": "true"}, {"number": "56", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "57", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "58", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "59", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "60", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "61", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "62", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "63", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "64", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "65", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "66", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "67", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "68", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "69", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "70", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "71", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "72", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "73", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "74", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "75", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "76", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "77", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "78", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "79", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "80", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "81", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "82", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "83", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "84", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "85", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "86", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "87", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "88", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "89", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "90", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "91", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "92", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "93", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "94", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "95", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "96", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "97", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "98", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "99", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "100", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "101", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "102", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "103", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "104", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "105", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "106", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "107", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "108", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "109", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "110", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "111", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "112", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "113", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "114", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "115", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "116", "ReferenceId": "18650841", "FullCitation": "Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841", "Include": "true"}, {"number": "117", "ReferenceId": "19143056", "FullCitation": "Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056", "Include": "true"}, {"number": "118", "ReferenceId": "20594292", "FullCitation": "Berge EO, et al. Mol. Cancer (2010) pmid: 20594292", "Include": "true"}, {"number": "119", "ReferenceId": "16936740", "FullCitation": "Giacinti C, et al. Oncogene (2006) pmid: 16936740", "Include": "true"}, {"number": "120", "ReferenceId": "9342358", "FullCitation": "Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358", "Include": "true"}, {"number": "121", "ReferenceId": "10486322", "FullCitation": "Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322", "Include": "true"}, {"number": "122", "ReferenceId": "1534305", "FullCitation": "Qin XQ, et al. Genes Dev. (1992) pmid: 1534305", "Include": "true"}, {"number": "123", "ReferenceId": "16360038", "FullCitation": "Rubin SM, et al. Cell (2005) pmid: 16360038", "Include": "true"}, {"number": "124", "ReferenceId": "16449662", "FullCitation": "Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662", "Include": "true"}, {"number": "125", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "126", "ReferenceId": "33015533", "FullCitation": "Williams EA, et al. JCO Precis Oncol (2020) pmid: 33015533", "Include": "true"}, {"number": "127", "ReferenceId": "8644845", "FullCitation": "Dei Tos AP, et al. Am. J. Pathol. (1996) pmid: 8644845", "Include": "true"}, {"number": "128", "ReferenceId": "22716012", "FullCitation": "Svajdler M, et al. Cesk Patol (2012) pmid: 22716012", "Include": "true"}, {"number": "129", "ReferenceId": "11232643", "FullCitation": "Derr\u00e9 J, et al. Lab. Invest. (2001) pmid: 11232643", "Include": "true"}, {"number": "130", "ReferenceId": "21125665", "FullCitation": "Gibault L, et al. J. Pathol. (2011) pmid: 21125665", "Include": "true"}, {"number": "131", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "132", "ReferenceId": "30373917", "FullCitation": "Gong X, et al. Cancer Discov (2019) pmid: 30373917", "Include": "true"}, {"number": "133", "ReferenceId": "30373918", "FullCitation": "Oser MG, et al. Cancer Discov (2019) pmid: 30373918", "Include": "true"}, {"number": "134", "ReferenceId": "34741392", "FullCitation": "Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392", "Include": "true"}, {"number": "135", "ReferenceId": "30232224", "FullCitation": "Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224", "Include": "true"}, {"number": "136", "ReferenceId": "21955141", "FullCitation": "Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141", "Include": "true"}, {"number": "137", "ReferenceId": "21875955", "FullCitation": "Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955", "Include": "true"}, {"number": "138", "ReferenceId": "24282159", "FullCitation": "Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159", "Include": "true"}, {"number": "139", "ReferenceId": "22553621", "FullCitation": "Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621", "Include": "true"}, {"number": "140", "ReferenceId": "21139478", "FullCitation": "Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478", "Include": "true"}, {"number": "141", "ReferenceId": "19959033", "FullCitation": "Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033", "Include": "true"}, {"number": "142", "ReferenceId": "15050739", "FullCitation": "Uray IP, et al. Cancer Lett. (2004) pmid: 15050739", "Include": "true"}, {"number": "143", "ReferenceId": "28416471", "FullCitation": "Farge T, et al. Cancer Discov (2017) pmid: 28416471", "Include": "true"}, {"number": "144", "ReferenceId": "24013230", "FullCitation": "van Oers JM, et al. Oncogene (2014) pmid: 24013230", "Include": "true"}, {"number": "145", "ReferenceId": "24556366", "FullCitation": "Dietlein F, et al. Cancer Discov (2014) pmid: 24556366", "Include": "true"}, {"number": "146", "ReferenceId": "18922920", "FullCitation": "Haugen AC, et al. Cancer Res. (2008) pmid: 18922920", "Include": "true"}, {"number": "147", "ReferenceId": "20708618", "FullCitation": "Lee SY, et al. Gastroenterology (2010) pmid: 20708618", "Include": "true"}, {"number": "148", "ReferenceId": "24691426", "FullCitation": "Watson MM, et al. Br. J. Cancer (2014) pmid: 24691426", "Include": "true"}, {"number": "149", "ReferenceId": "24209623", "FullCitation": "Kim TM, et al. Cell (2013) pmid: 24209623", "Include": "true"}, {"number": "150", "ReferenceId": "11470537", "FullCitation": "Ohmiya N, et al. Gene (2001) pmid: 11470537", "Include": "true"}, {"number": "151", "ReferenceId": "22496206", "FullCitation": "Laghi L, et al. Clin. Cancer Res. (2012) pmid: 22496206", "Include": "true"}, {"number": "152", "ReferenceId": "14871813", "FullCitation": "Plaschke J, et al. Cancer Res. (2004) pmid: 14871813", "Include": "true"}, {"number": "153", "ReferenceId": "26617824", "FullCitation": "Miao HK, et al. Int J Clin Exp Pathol (2015) pmid: 26617824", "Include": "true"}, {"number": "154", "ReferenceId": "28528517", "FullCitation": "Morak M, et al. Fam. Cancer (2017) pmid: 28528517", "Include": "true"}, {"number": "155", "ReferenceId": "21128252", "FullCitation": "Duraturo F, et al. Int. J. Cancer (2011) pmid: 21128252", "Include": "true"}, {"number": "156", "ReferenceId": "21974800", "FullCitation": "Reeves SG, et al. Cancer Epidemiol (2012) pmid: 21974800", "Include": "true"}, {"number": "157", "ReferenceId": "17205513", "FullCitation": "Berndt SI, et al. Int. J. Cancer (2007) pmid: 17205513", "Include": "true"}, {"number": "158", "ReferenceId": "25927356", "FullCitation": "Yang X, et al. PLoS ONE (2015) pmid: 25927356", "Include": "true"}, {"number": "159", "ReferenceId": "22623965", "FullCitation": "Vogelsang M, et al. PLoS ONE (2012) pmid: 22623965", "Include": "true"}, {"number": "160", "ReferenceId": "23464402", "FullCitation": "Jafary F, et al. Asian Pac. J. Cancer Prev. (2012) pmid: 23464402", "Include": "true"}, {"number": "161", "ReferenceId": "18355840", "FullCitation": "Hirata H, et al. J. Urol. (2008) pmid: 18355840", "Include": "true"}, {"number": "162", "ReferenceId": "25598504", "FullCitation": "Nogueira GA, et al. Int. J. Cancer (2015) pmid: 25598504", "Include": "true"}, {"number": "163", "ReferenceId": "27476653", "FullCitation": "Adam R, et al. Am. J. Hum. Genet. (2016) pmid: 27476653", "Include": "true"}, {"number": "164", "ReferenceId": "10706084", "FullCitation": "Edelmann W, et al. Cancer Res. (2000) pmid: 10706084", "Include": "true"}, {"number": "165", "ReferenceId": "22249440", "FullCitation": "Plaschke J, et al. Int J Colorectal Dis (2012) pmid: 22249440", "Include": "true"}, {"number": "166", "ReferenceId": "9650548", "FullCitation": "Benachenhou N, et al. Int. J. Cancer (1998) pmid: 9650548", "Include": "true"}, {"number": "167", "ReferenceId": "15541380", "FullCitation": "Kawakami T, et al. Biochem. Biophys. Res. Commun. (2004) pmid: 15541380", "Include": "true"}, {"number": "168", "ReferenceId": "10098729", "FullCitation": "Benachenhou N, et al. Br. J. Cancer (1999) pmid: 10098729", "Include": "true"}, {"number": "169", "ReferenceId": "25966119", "FullCitation": "Xu XL, et al. Genet. Mol. Res. (2015) pmid: 25966119", "Include": "true"}, {"number": "170", "ReferenceId": "21212431", "FullCitation": "Dong X, et al. Oncologist (2011) pmid: 21212431", "Include": "true"}, {"number": "171", "ReferenceId": "21285347", "FullCitation": "Takahashi M, et al. J. Biol. Chem. (2011) pmid: 21285347", "Include": "true"}, {"number": "172", "ReferenceId": "23724141", "FullCitation": "Park JM, et al. PLoS ONE (2013) pmid: 23724141", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_11_28 20:03:53", "OpName": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "794x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "6 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SOFT TISSUE", "disease_ontology": "Unknown primary leiomyosarcoma", "flowcell_analysis": "2000025017", "gender": "female", "pathology_diagnosis": "Leiomyosarcoma", "percent_tumor_nuclei": "60", "pipeline_version": "v3.15.0", "purity_assessment": "93.0", "specimen": "ORD_1503257_01*US1439901.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1503257_01", "test_type": "HemeComplete", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "R2", "mean_exon_depth": "509.72", "name": "SQ_US1439901.01_1", "nucleic_acid_type": "RNA"}, {"bait_set": "D2", "mean_exon_depth": "811.6", "name": "SQ_US1439901.01_2", "nucleic_acid_type": "DNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4867", "cds_effect": "2627T>C", "depth": "713", "equivocal": "false", "functional_effect": "missense", "gene": "GRIN2A", "percent_reads": "48.67", "position": "chr16:9858774", "protein_effect": "I876T", "status": "unknown", "strand": "_", "transcript": "NM_000833", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.655", "cds_effect": "1813G>A", "depth": "571", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB1", "percent_reads": "65.5", "position": "chr3:134898755", "protein_effect": "E605K", "status": "unknown", "strand": "+", "transcript": "NM_004441", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.4849", "cds_effect": "833A>C", "depth": "596", "equivocal": "false", "functional_effect": "missense", "gene": "CREBBP", "percent_reads": "48.49", "position": "chr16:3860746", "protein_effect": "Q278P", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.7175", "cds_effect": "22delT", "depth": "223", "equivocal": "false", "functional_effect": "frameshift", "gene": "MSH3", "percent_reads": "71.75", "position": "chr5:79950567", "protein_effect": "S8fs*17", "status": "likely", "strand": "+", "transcript": "NM_002439", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.9", "cds_effect": "550G>T", "depth": "40", "equivocal": "false", "functional_effect": "missense", "gene": "MYCN", "percent_reads": "90.0", "position": "chr2:16082736", "protein_effect": "A184S", "status": "unknown", "strand": "+", "transcript": "NM_005378", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.6593", "cds_effect": "1027C>G", "depth": "681", "equivocal": "false", "functional_effect": "missense", "gene": "TLL2", "percent_reads": "65.93", "position": "chr10:98172970", "protein_effect": "R343G", "status": "unknown", "strand": "_", "transcript": "NM_012465", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.4986", "cds_effect": "2201C>T", "depth": "740", "equivocal": "false", "functional_effect": "missense", "gene": "CIC", "percent_reads": "49.86", "position": "chr19:42795121", "protein_effect": "S734L", "status": "unknown", "strand": "+", "transcript": "NM_015125", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.4666", "cds_effect": "332_333delCA", "depth": "928", "equivocal": "false", "functional_effect": "frameshift", "gene": "CD36", "percent_reads": "46.66", "position": "chr7:80290428", "protein_effect": "T111fs*22", "status": "likely", "strand": "+", "transcript": "NM_000072", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.9475", "cds_effect": "1025G>C", "depth": "552", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "94.75", "position": "chr17:7574002", "protein_effect": "R342P", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.3591", "cds_effect": "839C>T", "depth": "557", "equivocal": "false", "functional_effect": "missense", "gene": "ASMTL", "percent_reads": "35.91", "position": "chrX:1546685", "protein_effect": "T280I", "status": "unknown", "strand": "_", "transcript": "NM_004192", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"allele_fraction": "0.6223", "cds_effect": "1319C>T", "depth": "564", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "62.23", "position": "chr4:55138642", "protein_effect": "T440M", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "7", "equivocal": "true", "gene": "ERG", "number_of_exons": "10 of 10", "position": "chr21:39755324_39947669", "ratio": "2.17", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"copy_number": "7", "equivocal": "true", "gene": "RUNX1", "number_of_exons": "9 of 9", "position": "chr21:36164431_36421229", "ratio": "1.89", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"copy_number": "11", "equivocal": "false", "gene": "STAG2", "number_of_exons": "33 of 33", "position": "chrX:123156434_123234500", "ratio": "3.14", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"copy_number": "8", "equivocal": "false", "gene": "IL7R", "number_of_exons": "8 of 8", "position": "chr5:35857055_35876588", "ratio": "2.3", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"copy_number": "7", "equivocal": "true", "gene": "U2AF1", "number_of_exons": "10 of 10", "position": "chr21:44513211_44527647", "ratio": "2.03", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"copy_number": "10", "equivocal": "false", "gene": "RICTOR", "number_of_exons": "39 of 39", "position": "chr5:38942378_39074519", "ratio": "2.91", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}]}, "rearrangements": {"rearrangement": [{"description": "NF1(NM_001042492) rearrangement exon 47", "equivocal": "false", "in_frame": "unknown", "other_gene": "CDRT1", "pos1": "chr17:29667379_29667534", "pos2": "chr17:15500083_15500317", "status": "unknown", "supporting_read_pairs": "140", "targeted_gene": "NF1", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"description": "KCNMB2(NM_005832)_ETV5(NM_004454) fusion (K1; E6*)", "equivocal": "false", "in_frame": "unknown", "other_gene": "KCNMB2", "pos1": "chr3:185798243_185798945", "pos2": "chr3:178429065_178429616", "status": "unknown", "supporting_read_pairs": "278", "targeted_gene": "ETV5", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"description": "ETV5(NM_004454) rearrangement intron 6", "equivocal": "false", "in_frame": "unknown", "other_gene": "KCNMB2", "pos1": "chr3:185798252_185799008", "pos2": "chr3:178425450_178425563", "status": "unknown", "supporting_read_pairs": "51", "targeted_gene": "ETV5", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"description": "ETV5(NM_004454) rearrangement intron 6", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr3:185798395_185798695", "pos2": "chr3:153699883_153700120", "status": "unknown", "supporting_read_pairs": "108", "targeted_gene": "ETV5", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1439901.01_2"}}, {"description": "truncation", "equivocal": "false", "in_frame": "unknown", "other_gene": "ENOX1", "pos1": "chr13:48878094_48878134", "pos2": "chr13:44241609_44241649", "status": "likely", "supporting_read_pairs": "55", "targeted_gene": "RB1", "type": "truncation", "rna_evidence": {"sample": "SQ_US1439901.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "5.7", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}